Compound Detail
CHEMBL654
MIRTAZAPINE 💊 Approved Drug
Enter ChEMBL ID:
Free Research Context
This compound will appear in recent viewed items on the research home for this browser.
Research home
View demo workspace
💊 Approved Drug
Basic Information
| ChEMBL ID | CHEMBL654 |
| Name | MIRTAZAPINE |
| Phase | Approved |
| Structure Type | MOL |
| InChI Key | RONZAEMNMFQXRA-UHFFFAOYSA-N |
| Therapeutic | ✓ Yes |
18
Targets
26
Activities
3
Assay Types
21
PK Parameters
20
Publications
15
Known Names
20
Indications
3
Mechanisms
Molecular Properties
265.4
MW (Da)
2.48
ALogP
3
HBA
0
HBD
19.4
PSA (Ų)
0.73
QED
0
Ro5 Violations
0
Rot. Bonds
Drug Information
| Molecule Type | Small molecule |
| First Approval | 1996 |
| Availability | Prescription |
| Chirality | Racemic |
Mechanism of Action
| Mechanism | Action Type | Target | Direct | Efficacy |
|---|---|---|---|---|
| Serotonin 2a (5-HT2a) receptor antagonist | ANTAGONIST | 5-hydroxytryptamine receptor 2A | ✓ | ✓ |
| Serotonin 2c (5-HT2c) receptor antagonist | ANTAGONIST | 5-hydroxytryptamine receptor 2C | ✓ | ✓ |
| Adrenergic receptor alpha-2 antagonist | ANTAGONIST | Adrenergic receptor alpha-2 | ✓ | ✓ |
Indications
Depressive Disorder Depressive Disorder Depressive Disorder, Major Sleep Initiation and Maintenance Disorders Anxiety Child Development Disorders, Pervasive Dementia Heroin Dependence Nausea Schizophrenia Alcoholism Amphetamine-Related Disorders Anorexia Anorexia Nervosa Cachexia Cocaine-Related Disorders Fibromyalgia Paraganglioma Substance-Related Disorders Substance-Related Disorders
ATC Classification
N06AX11
mirtazapine
Level 1: NERVOUS SYSTEM
Level 2: PSYCHOANALEPTICS
Drug Warnings
Black Box Warning
psychiatric toxicity
Activity Summary
Ki 19 meas. best 8.8
IC50 5 meas. best 7.07
Kd 2 meas. best 5.3
Target Activity Profile
| Target | Type | Best pChEMBL | Mean pChEMBL | Best (nM) | # Data |
|---|---|---|---|---|---|
| Histamine H1 receptor CHEMBL231 | Ki | 8.8 | 8.8 | 1.6 | 1 |
| 5-hydroxytryptamine receptor 2A CHEMBL322 | Ki | 8.7 | 8.265 | 2.0 | 2 |
| Unchecked CHEMBL612545 | Ki | 8.29 | 8.29 | 5.1 | 1 |
| 5-hydroxytryptamine receptor 2C CHEMBL324 | Ki | 8.26 | 8.26 | 5.5 | 1 |
| 5-hydroxytryptamine receptor 2A CHEMBL224 | Ki | 8.09 | 7.625 | 8.2 | 2 |
| Alpha-2C adrenergic receptor CHEMBL1916 | Ki | 7.75 | 7.75 | 18.0 | 1 |
| 5-hydroxytryptamine receptor 1A CHEMBL214 | Ki | 7.75 | 7.75 | 18.0 | 1 |
| Alpha-2A adrenergic receptor CHEMBL1867 | Ki | 7.7 | 7.7 | 20.0 | 1 |
| 5-hydroxytryptamine receptor 2C CHEMBL225 | Ki | 7.41 | 7.41 | 39.0 | 1 |
| Alpha-2A adrenergic receptor CHEMBL1867 | IC50 | 7.07 | 7.07 | 85.1 | 1 |
| Alpha-2C adrenergic receptor CHEMBL1916 | IC50 | 6.7 | 6.7 | 199.5 | 1 |
| Alpha-2B adrenergic receptor CHEMBL1942 | IC50 | 6.65 | 6.65 | 223.9 | 1 |
| Norepinephrine transporter CHEMBL304 | IC50 | 6.58 | 6.58 | 260.0 | 1 |
| 5-hydroxytryptamine receptor 7 CHEMBL3155 | Ki | 6.58 | 6.58 | 265.0 | 1 |
| Adrenergic receptor alpha-1 CHEMBL1907610 | Ki | 6.22 | 6.1 | 608.0 | 2 |
| D(2) dopamine receptor CHEMBL339 | Ki | 5.84 | 5.84 | 1460.0 | 1 |
| Norepinephrine transporter CHEMBL304 | Ki | 5.79 | 5.79 | 1640.0 | 1 |
| 5-hydroxytryptamine receptor 3A CHEMBL1899 | Ki | 5.54 | 5.54 | 2900.0 | 1 |
| Alpha-1A adrenergic receptor CHEMBL229 | IC50 | 5.5 | 5.5 | 3162.3 | 1 |
| D(1A) dopamine receptor CHEMBL265 | Ki | 5.38 | 5.38 | 4167.0 | 1 |
| 5-hydroxytryptamine receptor 1A CHEMBL214 | Kd | 5.3 | 5.3 | 5011.9 | 1 |
| D(3) dopamine receptor CHEMBL234 | Ki | 5.24 | 5.24 | 5723.0 | 1 |
Pharmacokinetic Data
| Parameter | Value | Units | Species |
|---|---|---|---|
| CL | 8.0 | mL.min-1.kg-1 | Homo sapiens |
| CL | 7.7 | mL.min-1.kg-1 | Homo sapiens |
| CL | 8.0 | mL.min-1.kg-1 | Homo sapiens |
| CL | 8.0 | mL.min-1.kg-1 | Homo sapiens |
| CL | 30.4 | mL.min-1.kg-1 | Mus musculus |
| CL | 6.3 | uL.min-1.(10^6cells)-1 | Homo sapiens |
| CL | 8.0 | mL.min-1.kg-1 | Homo sapiens |
| F | 79.0 | % | Homo sapiens |
| Fu | 0.15 | - | Homo sapiens |
| Fu | 0.08 | - | Rattus norvegicus |
| Fu | 0.15 | - | Homo sapiens |
| Fu | 0.15 | - | Homo sapiens |
| Fu | 0.16 | - | Not specified |
| Fu | 0.266 | - | Not specified |
| Fu | 0.286 | - | Not specified |
| Fu | 0.32 | - | Not specified |
| Fu | 0.15 | - | Homo sapiens |
| MRT | 8.8 | hr | Homo sapiens |
| T1/2 | 15.0 | hr | Homo sapiens |
| T1/2 | 6.0 | hr | Mus musculus |
| T1/2 | 15.0 | hr | Homo sapiens |
Activity Data Samples
Top measurements by pChEMBL value
Literature References
| PubMed | DOI | Target Context | # Activities |
|---|---|---|---|
| - | 10.6019/CHEMBL5724801 | HEK-293T | 304 |
| - | 10.6019/CHEMBL5724801 | Fibroblast | 304 |
| - | 10.6019/CHEMBL5058577 | U2OS | 304 |
| - | 10.6019/CHEMBL5724801 | U2OS | 304 |
| - | 10.6019/CHEMBL5058577 | HEK-293T | 304 |
| - | 10.6019/CHEMBL5058577 | Fibroblast | 304 |
| 16472241 | 10.2174/1570163043334794 | Hepatotoxicity | 18 |
| 22194678 | 10.1371/journal.pcbi.1002310 | Hepatotoxicity | 14 |
| 15646539 | 10.1016/s0399-8320(04)95062-2 | Unchecked | 11 |
| 15646539 | 10.1016/s0399-8320(04)95062-2 | NON-PROTEIN TARGET | 8 |
| 20070106 | 10.1021/jm901371v | Homo sapiens | 8 |
| - | 10.6019/CHEMBL5058564 | U2OS | 6 |
| 21098647 | 10.1124/dmd.110.036988 | ADMET | 5 |
| 15771415 | 10.1021/jm049632c | Rattus norvegicus | 5 |
| - | 10.6019/CHEMBL5209801 | Free fatty acid receptor 4 | 5 |
| - | 10.6019/CHEMBL5209801 | Type-1 angiotensin II receptor | 5 |
| - | 10.6019/CHEMBL5209801 | Glucagon-like peptide 1 receptor | 5 |
| - | 10.6019/CHEMBL5209801 | Sphingosine 1-phosphate receptor 1 | 5 |
| - | 10.6019/CHEMBL5209801 | Alpha-2A adrenergic receptor | 5 |
| - | 10.6019/CHEMBL5209801 | Apelin receptor | 5 |
Data from ChEMBL 36 via Core Engine